On May 24, 2024, the CGCS 2024 (5th) International Summit on Cell and Gene Therapy in China was held in Nanjing. The summit was initiated by the CGCS organizing committee and carried out the CGCS Awards Star Award selection activity in conjunction with expert review and online selection. Shandong Xinbo Pharmaceutical Research Co., Ltd. (hereinafter referred to as the "Company") has been recognized by the jury for its technical service capabilities and has been awarded the "2024 CGT CRO Cooperation Rising Star" award.

The CGCS Awards Rising Star Award is initiated by the CGCS Organizing Committee and jointly announced by CGCS organizing committee experts and online selection. The Morning Star "is a particularly bright" morning star "that appears on the eastern horizon at dawn, symbolizing the arrival of a new day. Every industry has a group of "Morning Star" enterprises that bring hope and guide the industry's direction during difficult times.

Since its establishment in 2010, the company has provided over 10000 non clinical research services to more than 540 pharmaceutical companies, new drug research institutions, and research institutes both domestically and internationally. According to domestic and international regulatory requirements, the company has completed non clinical evaluation studies on nearly 400 innovative drugs, covering small molecule compounds, biomolecules, new preventive and therapeutic vaccines, traditional Chinese medicine/natural medicines, and other fields. The company has assisted research and development units in obtaining over 100 clinical approvals for new drugs, and has accumulated project experience in non clinical evaluation of therapeutic vaccines, cell and gene therapy drugs.

In the field of non clinical evaluation of innovative drugs in cell and gene therapy, mRNA and small nucleic acid, the company has established corresponding technology platforms and detection methods. Among them, the two test substances evaluated by the company in 2023- mRNA vaccine (acceptance number: CXSL2300483) and iNKT cell product GKL-006 injection (acceptance number: CXSL2300567) - have obtained clinical trial approval.

The company will continue to enhance its non clinical evaluation technology service capabilities to support global pharmaceutical research and development as well as the development of the healthcare industry.